Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

S. Rossi, V. Di Noia, L. Tonetti, A. Strippoli, M. Basso, G. Schinzari, A. Cassano, A. Leone, C. Barone, E. D'Argento

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. Patients & methods: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men, and nonsarcopenic patients. Results: Sarcopenia does not affect response to gefitinib treatment in EGFR mutated NSCLC patients, even if it is a bad prognostic indicator for overall survival (p = 0.035). Conclusion: Early recognition of sarcopenia is beneficial for prevention of cancer cachexia and detection of patients at potential risk of serious adverse events. Gefitinib dosage should be reduced and modulated in sarcopenic patients. © 2018 2018 Future Medicine Ltd.
Original languageEnglish
Pages (from-to)919-926
Number of pages8
JournalFuture Oncology
Volume14
Issue number10
DOIs
Publication statusPublished - 2018

Keywords

  • epidermal growth factor receptor
  • gefitinib
  • genomic DNA
  • antineoplastic agent
  • EGFR protein, human
  • protein kinase inhibitor
  • quinazoline derivative, adult
  • aged
  • Article
  • cancer prognosis
  • clinical article
  • controlled study
  • diarrhea
  • DNA extraction
  • drug dose reduction
  • drug tolerability
  • EGFR gene
  • exon
  • fatigue
  • female
  • gene mutation
  • human
  • interstitial lung disease
  • male
  • muscle mass
  • non small cell lung cancer
  • overall survival
  • polymerase chain reaction
  • priority journal
  • progression free survival
  • quality of life
  • rash
  • retrospective study
  • sarcopenia
  • skeletal muscle
  • treatment outcome
  • treatment response
  • very elderly
  • cachexia
  • complication
  • dose response
  • genetics
  • lung tumor
  • middle aged
  • mortality
  • mutation
  • prognosis
  • survival analysis, Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Cachexia
  • Carcinoma, Non-Small-Cell Lung
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Mutation
  • Prognosis
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptor, Epidermal Growth Factor
  • Retrospective Studies
  • Sarcopenia
  • Survival Analysis
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?'. Together they form a unique fingerprint.

Cite this